Compare AbbVie Inc (ABBV) vs Innovative Industrial Properties Inc (IIPR) Price & Performance

AbbVie (ABBV) trades at $253.61, down 0.45% on the day, with strong technical momentum showing bullish moving averages and key support at $253. The company reported Q1 2026 EPS of $2.65, beating expectations, while revenue growth is supported by Skyrizi and Rinvoq offsetting Humira declines. Analysts maintain a bullish consensus with 68% buy ratings and a $266.33 price target, representing 5% upside potential.

The outlook remains positive with robust immunology portfolio performance and dividend growth, though risks include patent cliffs in the 2030s and competitive pressures. Current valuation metrics appear elevated with P/E at 124.83, requiring sustained earnings growth to justify premium multiples. The stock offers income appeal with consistent dividend payments while navigating portfolio transition.

IIPR trades at $61.81, down 2.51% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported a Q1 2026 EPS beat of $1.88 versus $1.07 expected, though revenue has declined from $310M in 2023 to $266M in 2025. Recent news highlights progress on cannabis rescheduling as a potential tailwind and the declaration of a $1.90 dividend for Q2 2026.

The outlook is mixed; a high dividend yield and low P/E of 15.78 offer value, but declining revenue and negative net cash flow pose risks. Analyst sentiment is cautious with a majority Hold rating. Upside depends on stabilizing tenant operations and regulatory progress, while downside risks include further revenue pressure and sector volatility.